Puma Biotechnology grants shares. TD Cowen targets Puma Biotechnology stock at USD 6.00

Published on 10/14/2026 at 05:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached USD 56.50 million, up from USD 49.20 million. Puma Biotechnology stock has a USD 515.1 million market value on October 13, 2026.

Shares, revenue and reporting date

An inducement award covered 7,500 shares on October 5, 2026.
Second-quarter revenue reached USD 56.50 million versus USD 49.20 million a year earlier.
Puma Biotechnology is estimated to report third-quarter results on November 5, 2026.
Market capitalization stood at USD 515.1 million on October 13, 2026.

PBYI, US74587V1070, Illustration mit AI erstellt.

Puma Biotechnology (ISIN US74587V1070) granted 7,500 shares on October 5, 2026, while TD Cowen targeted the stock at USD 6.00 after raising its target from USD 5.00 on August 7, 2026. The award and the target frame a company that is balancing commercial revenue from NERLYNX with continued investment in alisertib trials.

Three dated company developments

On August 6, 2026, Puma reported second-quarter revenue of USD 56.50 million and GAAP net income of USD 8.20 million, according to Benzinga.

On September 17, 2026, the company initiated ALISCA-Lung2, a Phase II trial combining alisertib with paclitaxel for advanced small cell lung cancer, as listed on Puma Biotechnology. On October 5, 2026, the company announced an inducement restricted stock unit award covering 7,500 shares for a new non-executive employee, according to Yahoo Finance.

What the award means

The October award is tied to employment rather than a change in the drug pipeline. The restricted stock units vest over three years, with one-third vesting on the first anniversary of the October 1, 2026 vesting commencement date, according to Yahoo Finance.

For the operating picture, second-quarter product revenue was USD 53.60 million, compared with USD 42.00 million in the first quarter of 2026 and USD 49.20 million in the second quarter of 2025. GAAP net income of USD 8.20 million followed a GAAP net loss of USD 3.80 million in the first quarter, according to Benzinga.

Revenue growth meets a valuation gap

Puma guided to fiscal-year 2026 net NERLYNX product revenue of USD 205.00 million to USD 209.00 million, above its previous USD 202.00 million to USD 206.00 million range. Full-year net income guidance also rose to USD 17.00 million to USD 20.00 million from USD 16.00 million to USD 19.00 million, according to Benzinga.

That operating progress contrasts with TD Cowen's USD 6.00 price target, which remains below the USD 10.12 primary-market quote shown for October 13, 2026 in the MarketBeat report. The same report said the stock had reached a 52-week high of USD 10.15 on October 9, 2026, while its 52-week range in the October 13 market snapshot was USD 4.58 to USD 10.50.

November reporting date

MarketBeat estimates that Puma Biotechnology will report third-quarter 2026 results on November 5, 2026, after the market close, with an earnings call scheduled for 4:30 p.m. ET. Its estimate calls for revenue of USD 57.50 million and earnings per share of USD 0.09, compared with USD 54.48 million and USD 0.21 in the year-earlier quarter.

Market capitalization stood at USD 515.1 million on October 13, 2026. The combination of a higher 2026 revenue outlook, a developing alisertib pipeline and a USD 6.00 analyst target gives the November report a clear test of whether commercial momentum is translating into durable earnings.

Market context: Market report S&P 500.